{
    "Variants Include": [
        {
            "Gene": "a - synuclein (a - syn)",
            "variants": [
                {
                    "HGVS": "N.D. (API standardization not possible without more details. From literature it seems to be related to a missense mutation in a - syn gene, likely in cDNA leading to A53T change in protein. But exact HGVS not given)",
                    "cDNA Change": {
                        "transcript": "N.D.",
                        "ref": "N.D.",
                        "alt": "N.D.",
                        "position": "N.D."
                    },
                    "Protein Change": {
                        "ref": "A (Alanine)",
                        "alt": "T (Threonine)",
                        "position": "53"
                    },
                    "Description in input context": "A53T a - syn gene mutation"
                }
            ]
        }
    ],
    "Described Disease": {
        "Described Disease": "Parkinson's disease (PD), specifically familial PD with A53T a - syn mutation",
        "MONDO": "MONDO:0007673 (Retrieved from MONDO database for Parkinson's disease)"
    },
    "Experiment Method": [
        {
            "Assay Method": "Immunohistochemical analysis of postmortem tissue",
            "Material used": {
                "Material Source": "Patients Derived Material",
                "Material Name": "Brain tissue from patient IX - 51 of the Contursi kindred",
                "Description": "The patient (IX - 51) of the Contursi kindred, at autopsy, left half of the brain including brainstem was fixed in formalin and right half was frozen. Blocks of tissue from selected areas of the left hemisphere were used for immunohistochemistry."
            },
            "Readout type": "Qualitative",
            "Readout description": [
                {
                    "Variant": "N.D. (HGVS not available)",
                    "Conclusion": "Abnormal (presence of insoluble filamentous a - syn lesions and tau pathology)",
                    "Molecular Effect": "N.D.",
                    "Result Description": "Insoluble filamentous a - syn lesions were detected in almost all brain regions. Accumulation of insoluble nitrated a - syn was observed. Significant accumulations of filamentous insoluble tau protein were detected in some brain regions. Large spheroids were notable in certain regions, and spongiform change was noted in several cortical regions. Some spheroids showed tau immunoreactivity, and neuritic pathology was typically positive for either tau or a - syn but not both."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "Absence of insoluble a - syn and tau lesions (Custom, based on the knowledge that in normal conditions these abnormal protein aggregations are not present)",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Presence of insoluble a - syn and tau lesions (Custom, based on the knowledge that these are hallmarks of the disease)",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes (Immunohistochemistry is a commonly used method to study protein localization and pathology in PD)"
            }
        },
        {
            "Assay Method": "Biochemical analysis of postmortem tissue",
            "Material used": {
                "Material Source": "Patients Derived Material",
                "Material Name": "Frozen brain tissue from cingulate cortex, midfrontal cortex, cerebellum, hippocampus and 10 different subcortical areas of patient IX - 51",
                "Description": "One - gram samples of frozen brain tissue from some regions and 0.15 g samples from subcortical areas were fractionated based on differential extractability using buffered solutions of increasing solubilization strengths."
            },
            "Readout type": "Quantitative (protein levels analyzed by SDS - PAGE and Western blotting)",
            "Readout description": [
                {
                    "Variant": "N.D. (HGVS not available)",
                    "Conclusion": "Abnormal (altered solubility of a - syn and presence of nitrated a - syn and insoluble tau)",
                    "Molecular Effect": "N.D.",
                    "Result Description": "A significant portion of a - syn in cingulate cortex from case IX - 51 was extractable only with SDS or FA. Insoluble a - syn was widespread in many brain regions. Nitrated a - syn was present in hippocampus and cingulate cortex. Significant levels of insoluble tau were detected in several brain regions, and the tau isoform profile was similar to that of insoluble hyperphosphorylated filamentous tau in AD and other tauopathies."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "Normal levels of soluble a - syn and absence of nitrated a - syn and insoluble tau (Custom, based on the knowledge of normal protein status)",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Altered levels of soluble a - syn, presence of nitrated a - syn and insoluble tau (Custom, based on the knowledge of disease - associated protein changes)",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes (Biochemical fractionation and Western blotting are standard methods for studying protein solubility and modification in PD)"
            }
        },
        {
            "Assay Method": "Analysis of tau isoform composition",
            "Material used": {
                "Material Source": "Patients Derived Material",
                "Material Name": "Insoluble tau from the hippocampus and dorsal pons of patient IX - 51",
                "Description": "Insoluble tau from the hippocampus and dorsal pons was dephosphorylated with Escherichia coli alkaline phosphatase for analysis."
            },
            "Readout type": "Qualitative (isoform composition determination)",
            "Readout description": [
                {
                    "Variant": "N.D. (HGVS not available)",
                    "Conclusion": "Abnormal (isoform composition similar to AD and distinct from other tauopathies)",
                    "Molecular Effect": "N.D.",
                    "Result Description": "The insoluble tau isolated from this case was composed of both three - repeat and four - repeat tau isoforms, similar to AD and distinct from other tauopathies such as PSP and CBD."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "Normal tau isoform composition (Custom, based on the knowledge of normal tau isoforms in non - diseased state)",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Abnormal tau isoform composition as seen in AD - like pattern (Custom, based on the knowledge of disease - associated tau isoform changes)",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes (Analysis of tau isoform composition is a relevant method for studying tauopathies associated with PD)"
            }
        },
        {
            "Assay Method": "Ultrastructural analysis of postmortem tissue",
            "Material used": {
                "Material Source": "Patients Derived Material",
                "Material Name": "Selected brain sections from patient IX - 51",
                "Description": "Selected brain sections were used for immunoelectron microscopy (EM) studies."
            },
            "Readout type": "Qualitative (visualization of ultrastructure)",
            "Readout description": [
                {
                    "Variant": "N.D. (HGVS not available)",
                    "Conclusion": "Abnormal (presence of characteristic spheroids with filamentous ultrastructure for a - syn and tau fibrils)",
                    "Molecular Effect": "N.D.",
                    "Result Description": "Immuno - EM studies of inclusions labeled with antibodies to a - syn revealed characteristic spheroids with filamentous ultrastructure. Inclusions containing tau fibrils were also detected. Isolated sarkosyl - insoluble material from hippocampus and dorsal pons contained a - syn and tau filaments similar to those in other neurodegenerative diseases."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "Absence of abnormal filamentous structures (Custom, based on the knowledge of normal brain ultrastructure)",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Presence of abnormal filamentous structures characteristic of a - syn and tau fibrils (Custom, based on the knowledge of disease - associated ultrastructural changes)",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes (Ultrastructural analysis by EM is a standard method for studying protein aggregates in neurodegenerative diseases)"
            }
        },
        {
            "Assay Method": "Isolation of dispersed a - syn and tau filaments",
            "Material used": {
                "Material Source": "Patients Derived Material",
                "Material Name": "Hippocampus (for a - syn) and dorsal pons (for tau) of patient IX - 51",
                "Description": "Tissue from hippocampus and dorsal pons was homogenized and processed to isolate dispersed a - syn and tau filaments."
            },
            "Readout type": "Qualitative (visualization of filaments)",
            "Readout description": [
                {
                    "Variant": "N.D. (HGVS not available)",
                    "Conclusion": "Abnormal (presence of a - syn and tau filaments)",
                    "Molecular Effect": "N.D.",
                    "Result Description": "Filaments extracted from hippocampus and dorsal pons were immunolabeled and visualized by EM, showing the presence of a - syn and tau filaments."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "Absence of a - syn and tau filaments (Custom, based on the knowledge of normal brain filament status)",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Presence of a - syn and tau filaments (Custom, based on the knowledge of disease - associated filament formation)",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes (Isolation and visualization of filaments is a relevant method for studying protein aggregation in PD)"
            }
        },
        {
            "Assay Method": "In vitro fibril formation assays",
            "Material used": {
                "Material Source": "Recombinant proteins",
                "Material Name": "Bacterial recombinant tau T40, recombinant wild - type (WT) and A53T mutant a - syn",
                "Description": "These recombinant proteins were used for in vitro fibril formation assays."
            },
            "Readout type": "Quantitative (quantification of fibrils using K114 binding and sedimentation analysis)",
            "Readout description": [
                {
                    "Variant": "N.D. (HGVS not available)",
                    "Conclusion": "Abnormal (enhanced fibrillization for A53T mutant a - syn compared to WT a - syn)",
                    "Molecular Effect": "Enhanced fibrillization (both self - assembly of a - syn and promotion of tau fibrillization)",
                    "Result Description": "Fibril assembly was much faster for A53T compared to WT a - syn. Co - assembly experiments showed that the rates of assembly of a - syn and tau were accelerated when A53T instead of WT a - syn was used."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "Yes",
                "Description": "n = 4 samples (implies 4 biological replicates)"
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "Normal rate of fibrillization for WT a - syn and tau (Custom, based on the knowledge of normal protein fibrillization rate)",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Enhanced rate of fibrillization as seen with A53T mutant a - syn (Custom, based